Nabriva Therapeutics Financial Health

Short Term Liabilities: NBRV's short term assets ($47.6M) exceed its short term liabilities ($21.6M).

Long Term Liabilities: NBRV's short term assets ($47.6M) exceed its long term liabilities ($977.0K).

Debt Level: NBRV has more cash than its total debt.

Reducing Debt: NBRV's debt to equity ratio has increased from 0.2% to 23.9% over the past 5 years.

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: NBRV has less than a year of cash runway based on its current free cash flow.

Forecast Cash Runway: NBRV has less than a year of cash runway if free cash flow continues to reduce at historical rates of 0.2% each year

• Healthy companies in the Pharmaceuticals & Biotech industry.